Table 1. Details, by efficacy trial number, of subunit vaccine formulations containing recombinant Hendra virus soluble G glycoprotein*.
| Trial no., horse identification | Hendra virus soluble G glycoprotein specification |
Challenge, days after vaccination | Viral infectivity control |
|||||
|---|---|---|---|---|---|---|---|---|
| Source | Irradiation | Dose, μg | Species | No. | ||||
| 1 | Horse | 1 | ||||||
| V1 | 293F HEK | No | 100 | 21 | ||||
| V2 |
293F HEK |
No |
100 |
|
21 |
|
|
|
| 2 | Guinea pig | 4 | ||||||
| V3 | 293F HEK | No | 50 | 21 | ||||
| V4 | 293F HEK | No | 50 | 21 | ||||
| V5 |
293F HEK |
No |
50 |
|
21 |
|
|
|
| 3 | Ferret | 2 | ||||||
| V6 | CHO | Yes | 100 | 21 | ||||
| V7 |
CHO |
Yes |
100 |
|
21 |
|
|
|
| 4 | Ferret | 2 | ||||||
| V8 | CHO | Yes | 100 | 194 | ||||
| V9 | CHO | Yes | 100 | 194 | ||||
| V10 | CHO | Yes | 100 | 194 | ||||
*HEK, human embryonic kidney cells; CHO, Chinese hamster ovary cells.